Sanofi Ventures and Children's Hospital Colorado have returned to back Q32 Bio, an immune regulation-focused university spinout that has now raised at least $106m to date.

Q32 Bio, a US-based immune regulation drug developer, closed a $60m series B round yesterday featuring Sanofi Ventures, the strategic investment arm of pharmaceutical firm Sanofi.

University of Colorado and healthcare provider Children’s Hospital Colorado’s Center for Innovation both participated in the round, which was co-led by OrbiMed and Acorn Bioventures and also backed by Osage University Partners, Atlas Venture, Abingworth and undisclosed additional investors.

Q32 Bio is developing drugs designed to regulate the patient’s immune system to fight off…